Ninety‐Six–Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV‐1 and Wild‐Type Hepatitis B Virus

Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis, Paris, France.
Clinical Infectious Diseases (Impact Factor: 8.89). 11/2004; 39(7):1062-4. DOI: 10.1086/424012
Source: PubMed


We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus
(HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination
therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV
infection is very promising in the treatment of HIV/HBV coinfection.

Full-text preview

Available from:

  • No preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tenofovir disoproxil fumarate (TDF) is an oral prodrug of tenofovir, a novel, acyclic nucleotide analogue with in vitro activity against HIV-1 and HIV-2. TDF is licensed by American Food and Drug Administration (FDA) in 2001 for the treat- ment of HIV infection. TDF is currently one of the most widely used nucleotide reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infec- tion. Its efficacy, favorable toxicity profile, and convenient dosing have made this drug one of the most popular first-line treatment. Numerous stud - ies have demonstrated the use of TDF in the treat- ment of HIV infection. It also has been shown to be effective in HIV/HBV coinfected patients and in patients with wild-type and lamivudine-resistant strains. Accumulating evidence suggests that TDF is more potent in suppressing HBV replication. In this review, we summarize the study progress of TDF in treating HBV infection.
    Preview · Article · Aug 2008 · World Chinese Journal of Digestology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic Hepatitis B, were considered in the development of these guidelines.3-7 The recommendations suggest pre- ferred approaches to the diagnostic, therapeutic, and pre- ventive aspects of care. They are intended to be flexible. Specific recommendations are based on relevant pub- lished information. In an attempt to characterize the qual- ity of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). These guidelines may be updated periodically as new information becomes available.
    Full-text · Article ·
Show more